IMPORTANCE Human papillomavirus (HPV) is a known causative agent for oropharyngeal squamous cell carcinoma (OPSCC). Whereas it is becoming more firmly established that HPV-positive head and neck squamous cell carcinoma is associated with better survival outcomes, believed to be because of better response to chemoradiation therapy, the specific mechanisms for these improved survival outcomes remain underexplored.
M ultiple risk factors are associated with the development of head and neck squamous cell carcinoma (HNSCC), the most common ones being tobacco and alcohol use. In addition to these, infection with the human papillomavirus (HPV) is also a causative agent for some HNSCC 1, 2 and an independent risk factor for oropharyngeal squamous cell carcinoma [3] [4] [5] (OPSCC). A recent meta-analysis of 5681 patients with HNSCC 6 found that the prevalence of HPV infection was significantly higher among patients with OPSCC (35.6%) than among those with oral (23.5%) or laryngeal squamous cell carcinoma. 7 Approximately 95% of these HNSCC subgroups contain high-risk HPV type 16 (HPV16) genomic DNA sequences. 8 Human papillomavirus status underlies HNSCC pathogenesis and is of clinical significance. Patients with HPVpositive tumors, particularly those with OPSCC, have improved prognosis. 3, 9 Whereas it is becoming more firmly established that HPV-positive HNSCC is associated with better survival outcomes, believed to be because of better response to chemoradiotherapy, 9 the specific mechanisms for these improved survival outcomes remain underexplored. Molecular alterations are known to occur early in HNSCC, 10 and epigenetic events of promoter hypermethylation represent important tumor-specific markers occurring early in tumor progression. Our group has demonstrated, using high-throughput methods, the contribution of both genetic 1 1 , 1 2 and epigenetic events, 1 3 often working together, 14 in the development and progression of HNSCC. 15 The goal of our study was to examine the status of HPV16 infection and methylation status of IGSF4, DAPK1, and ESR1, candidate genes associated with HNSCC pathogenesis, 14, 15 in an OPSCC cohort. 16 
Methods

Cohort
The retrospective study cohort comprised 121 patients with primary OPSCC. 16 To examine the relationship between HPV status and promoter methylation, variables included age, sex, race as self-reported, smoking, treatment (radiotherapy, chemotherapy), HPV16 status, and methylation status of IGSF4, DAPK1, and ESR1. This study was approved by the Henry Ford Health System institutional review board. Informed consent was waived due to the retrospective study design.
DNA Extraction
Whole 5-μm tissue sections or microdissected OPSCC lesions and adjacent normal tissue, when present, were processed for DNA extraction as previously described.
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HPV16 Detection by Means of Quantitative Polymerase Chain Reaction
Tumor HPV DNA concentrations were measured using a realtime quantitative polymerase chain reaction (PCR) system as previously described. 16 The cutoff value for HPV16-positive status was ≥0.03 (≥3 HPV genome copies/100 cells). 16, 18, 19 Bisulfite Modification and Quantitative Methylation-Specific Polymerase Chain Reaction (QMSP) Assay
Genomic DNA (100 ng) from formalin-fixed paraffinembedded OPSCC tissue and control universal methylated DNA (Chamicon International Inc) were modified using the EZ DNA methylation gold kit (Zymo Research) during which methylated DNA is protected and unmethylated cytosine is converted to uracil. 17 Quantitative methylation-specific PCR detects the presence of neoplastic DNA with a sensitivity of 1 cell in 1000. 20 This PCR approach is more sensitive than conventional PCR and more specific due to the use of an internally binding, fluorogenic hybridization probe. 21, 22 An advantage of QMSP is that it can measure the amount of methylation in a sample. Primers and probes were specifically designed to amplify IGSF4, DAPK1, and ESR1 genes. 23, 24 Primers and probes to an internal reference gene (ACTB) were run in parallel to standardize the input DNA. Polymerase chain reaction was carried out using the EpiTect MethyLight PCR Kit (Qiagen) according to the manufacturer's protocol in 96-well plates using the 7900HT Sequence detector (Applied Biosystems). Each plate included multiple water blanks and serial dilutions of a universal methylated positive control DNA (100 ng/μL, Chemicon), which was bisulfite converted in the laboratory for constructing the standard curve. These were run with the samples on each plate in duplicate. To determine the relative levels of methylated promoter DNA in each sample, the values of the gene of interest were compared with the values of the internal reference gene (ACTB) to obtain a ratio that is then multiplied by 100 to give a percentage value (gene of interest/reference gene × 100). The methylation results obtained by QMSP in our analysis were classified to give a binary status, in which any quantity of methylation in a sample was considered positive. 25 
Data Analysis
Univariate associations of HPV and methylation were analyzed using Fisher exact tests and by logistic regression for crude odds ratios, followed by multivariable logistic regression. Backward variable selection among genes was used to arrive at a final model. Univariate survival analyses were performed using log-rank tests. A multivariable Cox proportional hazards model was built to identify possible independent predictors of survival. Race, sex, HPV status, smoking, stage, treatment (radiotherapy and chemotherapy), and methylation were analyzed as categorical variables, whereas age was examined as a continuous variable. Statistical significance was set at P < .05, and all analyses were performed using SAS, version 9.2.
Results
Of the 121 primary OPSCCs, 67 were HPV negative and 51 HPV positive. 16 Caucasian race was associated with HPV positivity (71% vs 29% for AA race; P = .02). Comparison of methylation status of IGSF4, DAPK1, and ESR1 by HPV status demonstrated that IGSF4 was more frequently methylated in HPV-positive than HPV-negative patients (P = .004) ( Table 2 ). In univariate logistic regression analyses ( Univariate overall survival ( Table 4 ) was significantly associated with HPV status (P = .003), age (P = .04), smoking Table 5 ). The HPV-negative patients had 2.7 times the risk of death as compared with HPV-positive patients when all other variables were controlled for. Analysis of age, as a continuous measure, demonstrated that with every 1-year increase in age, the risk of death increased by a factor of 1.1. Patients treated with chemoradiation therapy had 3 times poorer survival than patients treated with radiation therapy only. The late-stage proportion (95%) among patients with chemoradiation treatments was higher than that for radiotherapy only (74%; adjusted P = .03). To offset a reduced cohort size of 75 patients with OPSCC (when all possible variables are accounted for), additional modeling with fewer predicators (predictors with univariate P values <.20) and a larger cohort size (n = 116), due to fewer patients being removed as a result of missing data, is presented in Table 5 . Human papillomavirus status, age, and treatment were retained together with smoking as independent predictors of survival.
Discussion
Oncogenic HPV, especially HPV16, accounts for approximately 95% of HPV infections in HNSCC. Several recent studies have shown that an HPV-positive status confers certain advantages to a subset of HNSCCs. Patients with HPV-positive HNSCCs have better survival outcomes than those with HPV-negative HNSCCs, believed to be because of better response to chemoradiation therapy. 9 However, the mechanism for this improved prognosis remains underexplored. Promoter hypermethylation is widely recognized as a mechanism in the progression of HNSCC. There is growing evidence that the DNA methylation regulatory pathways are targets for E6 and E7 oncogenes. 31 Genome-wide methylation differences between HPV-positive and HPV-negative tumors have been noted in squamous cell carcinoma cell lines 32 and primary HNSCC tumors. 33 In particular, promoter methylation of CCNA1 in HPV-positive cases with lower expression has been reported. 32, 34 In addition, epigenetic downregulation of this gene has been shown to be previously common in oral squamous cell carcinomas by means of pyrosequencing methylation assay.
35,36
In this study, IGSF4 was more frequently methylated in HPV-positive than HPV-negative patients with OPSCC (70% vs 41%, respectively; P = .004) and was an independent predictor of HPV-positive status (OR, 4.5; P = .005). Although the methylation rates of HPV-positive tumors are similar for DAPK1 and IGSF4 (61% and 70%, respectively), the P values reflect the difference in methylation rates relative to those seen in HPVnegative tumors. For DAPK1, there is only a 7% absolute difference (61% vs 54%), but for IGSF4 there is a 29% absolute difference (70% vs 41%). This explains the large difference between the respective P values. IGSF4 is frequently methylated in saliva from HNSCC tumors and in matched HPV16- achieved by allelic loss and promoter methylation. IGSF4 is located in the long arm of chromosome 11 at 11q23.2 and spans more than 300 kilobases. 38 In HNSCC, promoter hypermethylation of IGSF4 is a primary as well as a disease progression event.
14,15 IGSF4 hypermethylation is also a highly frequent event in cervical cancers, where its epigenetic silencing has been implicated in the progression from high-risk HPVcontaining, high-grade cervical intraepithelial neoplasia lesions to invasive cervical cancer. 40 Furthermore, IGSF4 silencing was accompanied by complete loss or significant decrease of IGSF4 mRNA expression in these cell lines. In esophageal squamous cell carcinoma (ESCC), loss of IGSF4 protein expression as a consequence of promoter hypermethylation, a late-stage event in ESCC carcinogenesis, has been implicated in invasion, metastasis, and aggressive tumor behavior through the disruption of cell-cell interactions. 41 A hypermethylated IGSF4 suggests a promising new therapeutic target in ESCC for restoration of gene expression by demethylating agents. 41 In this study, the significant association of IGSF4
with HPV-positive HNSCC suggests that HPV-positive tumors are to a greater extent driven by promoter hypermethylation in this tumor suppressor gene. From a clinical significance standpoint, recent studies are beginning to establish a mechanistic role for promoter methylation with improved survival outcomes in HPV-positive HNSCC. Gubanova et al 42 showed that promoter hypermethylation and concordant low SMG-1 expression not only was correlated with HPV-positive status and improved patient survival but also enhanced response to radiotherapy in HPVpositive HNSCC cell lines. A more recent study identified an HPV-related promoter methylation signature of 5 genes (derived from a more global discovery approach) with strong correlation to and strong predictive power for clinical outcome of patients with OPSCC. 43 Our study found no association of methylation and overall survival. This may be largely due to the candidate gene approach with only a limited number of genes. Even though IGSF4 methylation was associated with HPV positivity, it did not share HPV's association with survival. At the univariate level, AAs had poorer survival outcomes when compared with Caucasians (P = .008). In AAs with OPSCC, survival disparities are attributed to racial differences in the prevalence of HPV-positive tumors. 16, 29, 44, 45 African Americans had a significantly lower prevalence of HPVpositive tumors as compared with Caucasians, with corresponding worse survival for AAs. A recent study from our group 16 reported that HPV status has a substantial impact on overall survival in AAs with OPSCC. Among AAs, HPVpositive patients had better survival than HPV-negative patients (HR, 3.44; P = .001), a finding not previously reported, presumably due to a paucity of multiethnic cohorts and limited numbers of AA patients. The HPV-negative AA patients also did worse than both HPV-positive Caucasians and HPVnegative Caucasians. In this study, univariate survival analysis also showed that current smokers were more likely to die than never and past smokers (P = .003), with no difference in survival between never and past smokers. Tobacco use is one of the most common risk factors associated with the development of HNSCC. Most patients in our cohort had a history of smoking (87%). Recent studies have found that the risk of OPSCC progression and death increases as a direct result of tobacco exposure. 3, 46 Cox multivariate proportional hazards modeling retained HPV status, age, and treatment as independent predictors of overall survival in both Cox regression models. The HPVnegative patients had more than 2 times the risk of death as compared with HPV-positive patients. For every 1-year increase in age, the risk of death increased by a factor of 1.1, in keeping with studies showing increasing rate of cancer with age. Patients who received both radiotherapy and chemotherapy did worse than those with radiotherapy only, in both the univariate and multivariate models. The late-stage proportion (95%) among patients with chemoradiation treat- 
